ROIV Form 4: Eric Venker RSU tax withholding, 1.50M shares held

Rhea-AI Filing Summary

Roivant Sciences Ltd. insider transaction: A Form 4 reports that officer Eric Venker, President & Immunovant CEO, had 7,051 common shares of Roivant Sciences Ltd. withheld on 11/20/2025 at a price of $20.27 per share. The filing explains this was a "net settlement" of previously granted restricted stock units (RSUs) by the company to cover applicable tax withholding when those RSUs vested and settled.

After this tax-related share withholding, Venker directly beneficially owns 1,497,908 common shares of Roivant Sciences Ltd. This type of transaction does not represent an open-market sale, but rather an administrative step tied to equity compensation vesting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Venker Eric

Role President & Immunovant CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares	7,051	$20.27	$143K

Holdings After Transaction: Common Shares — 1,497,908 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Immunovant CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/20/2025		F		7,051(1)	D	$20.27	1,497,908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ROIV report in this Form 4?

The Form 4 reports that officer Eric Venker had 7,051 common shares of Roivant Sciences Ltd. withheld on 11/20/2025 in connection with the vesting and settlement of previously granted RSUs.

Was the ROIV insider transaction an open-market sale of shares?

No. The filing states the shares represent a "net settlement" of RSUs by Roivant Sciences Ltd. to satisfy tax withholding obligations upon RSU vesting, not an open-market sale.

How many ROIV shares does Eric Venker own after this transaction?

Following the reported transaction, Eric Venker beneficially owns 1,497,908 common shares of Roivant Sciences Ltd., held in direct ownership form.

What role does the reporting person hold at Roivant Sciences Ltd. (ROIV)?

The reporting person, Eric Venker, is listed as an Officer of Roivant Sciences Ltd. with the title President & Immunovant CEO.

What was the transaction price per ROIV share in this Form 4?

The Form 4 shows a transaction price of $20.27 per common share for the 7,051 shares used to satisfy tax withholding on vested RSUs.

Is this ROIV Form 4 filed by one reporting person or a group?

The Form 4 is indicated as being filed by one reporting person, not by more than one reporting person.